schliessen

Filtern

 

Bibliotheken

A novel scoring system predicts adjuvant chemolipiodolization benefit for hepatocellular carcinoma patients after hepatectomy.

Our aim in this study was to develop a prognostic scoring system with which to identify patients most likely to benefit from adjuvant chemolipiodolization (ACL) after liver resection for hepatocellular carcinoma (HCC). Data from 1150 HCC patients who underwent liver resection between 2002 and 2008 a... Full description

Journal Title: Oncotarget May 3, 2016, Vol.7(18), pp.25493-25506
Main Author: Huang, Li-Feng
Other Authors: Xing, Xianglei , Wu, Dong , Xia, Yong , Li, Jun , Wang, Kui , Yan, Zhen-Lin , Wan, Xu-Ying , Shi, Le-Hua , Yang, Tian , Lau, Wan Yee , Wu, Meng-Chao , Shen, Feng
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1949-2553 ; DOI: 10.18632/oncotarget.8333
Link: http://search.proquest.com/docview/1812878490/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest1812878490
title: A novel scoring system predicts adjuvant chemolipiodolization benefit for hepatocellular carcinoma patients after hepatectomy.
format: Article
creator:
  • Huang, Li-Feng
  • Xing, Xianglei
  • Wu, Dong
  • Xia, Yong
  • Li, Jun
  • Wang, Kui
  • Yan, Zhen-Lin
  • Wan, Xu-Ying
  • Shi, Le-Hua
  • Yang, Tian
  • Lau, Wan Yee
  • Wu, Meng-Chao
  • Shen, Feng
subjects:
  • Adult–Administration & Dosage
  • Aged–Mortality
  • Antineoplastic Agents–Therapy
  • Carcinoma, Hepatocellular–Methods
  • Chemoembolization, Therapeutic–Administration & Dosage
  • Chemotherapy, Adjuvant–Mortality
  • Combined Modality Therapy–Therapy
  • Ethiodized Oil–Therapy
  • Female–Therapy
  • Hepatectomy–Therapy
  • Humans–Therapy
  • Liver Neoplasms–Therapy
  • Male–Therapy
  • Middle Aged–Therapy
  • Prognosis–Therapy
  • Proportional Hazards Models–Therapy
  • Survival Analysis–Therapy
  • Antineoplastic Agents
  • Ethiodized Oil
  • Adjuvant Chemolipiodolization
  • Hepatocellular Carcinoma
  • Liver Resection
  • Prognosis
  • Scoring System
ispartof: Oncotarget, May 3, 2016, Vol.7(18), pp.25493-25506
description: Our aim in this study was to develop a prognostic scoring system with which to identify patients most likely to benefit from adjuvant chemolipiodolization (ACL) after liver resection for hepatocellular carcinoma (HCC). Data from 1150 HCC patients who underwent liver resection between 2002 and 2008 at the Eastern Hepatobiliary Surgery Hospital were used to develop the scoring system. Patients were stratified into prognostic subgroups using the new scoring system, and the outcomes of patients who received ACL and those who did not were compared in each subgroup. Using data from 379 patients operated on between 2008 and 2010 for validation, the scoring system had a concordance index (C-index) of 0.75 for predicting post-resectional overall survival (OS). It optimally stratified patients into three prognostic subgroups with scores of 0–5, 6–9 and ≥ 10, having better, medium and worse survival outcomes, respectively. A difference in OS between ACL and non-ACL patients was only detected in the subgroup with scores ≥ 10 (1-, 3-, and 5-year OS rates: 63.9%, 22.6%, and 9.0% vs. 33.8%, 5.6%, and 2.8%, p = 0.001). Our proposed scoring system provides an effective tool for selecting the patients most likely to benefit from ACL.
language: eng
source:
identifier: E-ISSN: 1949-2553 ; DOI: 10.18632/oncotarget.8333
fulltext: fulltext
issn:
  • 19492553
  • 1949-2553
url: Link


@attributes
ID315880637
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid1812878490
sourceidproquest
recordidTN_proquest1812878490
sourcesystemPC
pqid1812878490
display
typearticle
titleA novel scoring system predicts adjuvant chemolipiodolization benefit for hepatocellular carcinoma patients after hepatectomy.
creatorHuang, Li-Feng ; Xing, Xianglei ; Wu, Dong ; Xia, Yong ; Li, Jun ; Wang, Kui ; Yan, Zhen-Lin ; Wan, Xu-Ying ; Shi, Le-Hua ; Yang, Tian ; Lau, Wan Yee ; Wu, Meng-Chao ; Shen, Feng
contributorHuang, Li-Feng (correspondence author) ; Huang, Li-Feng (record owner)
ispartofOncotarget, May 3, 2016, Vol.7(18), pp.25493-25506
identifierE-ISSN: 1949-2553 ; DOI: 10.18632/oncotarget.8333
subjectAdult–Administration & Dosage ; Aged–Mortality ; Antineoplastic Agents–Therapy ; Carcinoma, Hepatocellular–Methods ; Chemoembolization, Therapeutic–Administration & Dosage ; Chemotherapy, Adjuvant–Mortality ; Combined Modality Therapy–Therapy ; Ethiodized Oil–Therapy ; Female–Therapy ; Hepatectomy–Therapy ; Humans–Therapy ; Liver Neoplasms–Therapy ; Male–Therapy ; Middle Aged–Therapy ; Prognosis–Therapy ; Proportional Hazards Models–Therapy ; Survival Analysis–Therapy ; Antineoplastic Agents ; Ethiodized Oil ; Adjuvant Chemolipiodolization ; Hepatocellular Carcinoma ; Liver Resection ; Prognosis ; Scoring System
languageeng
source
descriptionOur aim in this study was to develop a prognostic scoring system with which to identify patients most likely to benefit from adjuvant chemolipiodolization (ACL) after liver resection for hepatocellular carcinoma (HCC). Data from 1150 HCC patients who underwent liver resection between 2002 and 2008 at the Eastern Hepatobiliary Surgery Hospital were used to develop the scoring system. Patients were stratified into prognostic subgroups using the new scoring system, and the outcomes of patients who received ACL and those who did not were compared in each subgroup. Using data from 379 patients operated on between 2008 and 2010 for validation, the scoring system had a concordance index (C-index) of 0.75 for predicting post-resectional overall survival (OS). It optimally stratified patients into three prognostic subgroups with scores of 0–5, 6–9 and ≥ 10, having better, medium and worse survival outcomes, respectively. A difference in OS between ACL and non-ACL patients was only detected in the subgroup with scores ≥ 10 (1-, 3-, and 5-year OS rates: 63.9%, 22.6%, and 9.0% vs. 33.8%, 5.6%, and 2.8%, p = 0.001). Our proposed scoring system provides an effective tool for selecting the patients most likely to benefit from ACL.
version4
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/1812878490/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Huang, Li-Feng
1Xing, Xianglei
2Wu, Dong
3Xia, Yong
4Li, Jun
5Wang, Kui
6Yan, Zhen-Lin
7Wan, Xu-Ying
8Shi, Le-Hua
9Yang, Tian
10Lau, Wan Yee
11Wu, Meng-Chao
12Shen, Feng
titleA novel scoring system predicts adjuvant chemolipiodolization benefit for hepatocellular carcinoma patients after hepatectomy.
subject
0Adult–Administration & Dosage
1Aged–Mortality
2Antineoplastic Agents–Therapy
3Carcinoma, Hepatocellular–Methods
4Chemoembolization, Therapeutic–Administration & Dosage
5Chemotherapy, Adjuvant–Mortality
6Combined Modality Therapy–Therapy
7Ethiodized...
8adjuvant chemolipiodolization
9hepatocellular carcinoma
10liver resection
11prognosis
12scoring system
general
0English
110.18632/oncotarget.8333
2MEDLINE (ProQuest)
3ProQuest Biological Science Collection
4ProQuest Natural Science Collection
5ProQuest SciTech Collection
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
9Health Research Premium Collection
10Health Research Premium Collection (Alumni edition)
11Biological Science Index (ProQuest)
sourceidproquest
recordidproquest1812878490
issn
019492553
11949-2553
rsrctypearticle
creationdate2016
addtitleOncotarget
searchscope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
scope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
lsr43
01007527false
11007944false
21009130false
310000004false
410000038false
510000050false
610000120false
710000159false
810000238false
910000253false
1010000260false
1110000270false
1210000271false
1310000302false
1410000350false
contributorHuang, Li-Feng
startdate20160503
enddate20160503
citationpf 25493 pt 25506 vol 7 issue 18
lsr30VSR-Enriched:[pqid, description]
sort
titleA novel scoring system predicts adjuvant chemolipiodolization benefit for hepatocellular carcinoma patients after hepatectomy.
authorHuang, Li-Feng ; Xing, Xianglei ; Wu, Dong ; Xia, Yong ; Li, Jun ; Wang, Kui ; Yan, Zhen-Lin ; Wan, Xu-Ying ; Shi, Le-Hua ; Yang, Tian ; Lau, Wan Yee ; Wu, Meng-Chao ; Shen, Feng
creationdate20160503
lso0120160503
facets
frbrgroupid-1686425701425894922
frbrtype5
newrecords20181218
languageeng
creationdate2016
topic
0Adult–Administration & Dosage
1Aged–Mortality
2Antineoplastic Agents–Therapy
3Carcinoma, Hepatocellular–Methods
4Chemoembolization, Therapeutic–Administration & Dosage
5Chemotherapy, Adjuvant–Mortality
6Combined Modality Therapy–Therapy
7Ethiodized...
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Natural Science Collection
3ProQuest SciTech Collection
4Biological Science Database
5Natural Science Collection
6SciTech Premium Collection
7Health Research Premium Collection
8Health Research Premium Collection (Alumni edition)
9Biological Science Index (ProQuest)
prefilterarticles
rsrctypearticles
creatorcontrib
0Huang, Li-Feng
1Xing, Xianglei
2Wu, Dong
3Xia, Yong
4Li, Jun
5Wang, Kui
6Yan, Zhen-Lin
7Wan, Xu-Ying
8Shi, Le-Hua
9Yang, Tian
10Lau, Wan Yee
11Wu, Meng-Chao
12Shen, Feng
jtitleOncotarget
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Huang
1Xing
2Wu
3Xia
4Li
5Wang
6Yan
7Wan
8Shi
9Yang
10Lau
11Shen
aufirst
0Li-Feng
1Xianglei
2Dong
3Yong
4Jun
5Kui
6Zhen-Lin
7Xu-Ying
8Le-Hua
9Tian
10Wan Yee
11Meng-Chao
12Feng
au
0Huang, Li-Feng
1Xing, Xianglei
2Wu, Dong
3Xia, Yong
4Li, Jun
5Wang, Kui
6Yan, Zhen-Lin
7Wan, Xu-Ying
8Shi, Le-Hua
9Yang, Tian
10Lau, Wan Yee
11Wu, Meng-Chao
12Shen, Feng
addauHuang, Li-Feng
atitleA novel scoring system predicts adjuvant chemolipiodolization benefit for hepatocellular carcinoma patients after hepatectomy.
jtitleOncotarget
risdate20160503
volume7
issue18
spage25493
epage25506
pages25493-25506
eissn1949-2553
formatjournal
genrearticle
ristypeJOUR
doi10.18632/oncotarget.8333
urlhttp://search.proquest.com/docview/1812878490/
date2016-05-03